** Shares of Organovo Holdings ONVO.O more than tripled to $1.35 premarket
** ONVO says it is selling its FXR program, including lead asset FXR314, to Eli Lilly LLY.N
** ONVO's FXR program is focused on developing novel treatment approaches for inflammatory bowel disease
** LLY will pay ONVO $10 mln upfront and $50 mln if certain milestones are met in future, according to agreement
** LLY is acquiring all commercial and intellectual property rights to Organovo's FXR program for worldwide development
** Acquisition will allow Eli Lilly to further develop FXR314, starting from mid-stage, ONVO says
** ONVO fell ~68% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。